Cherie A. Stringer

Cherie A. Stringer

Auto-generated profile, based on publicly available information

Cherie A. Stringer

Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Neurobiology of Disease
Verified
Journal Article
Open access
CSCherie A. Stringer
Cherie A. Stringer
HMHaley K.S. Miyasato
Haley K.S. Miyasato
KCKevin A. Camey
Kevin A. Camey
KGKrina A. Ghadia
Krina A. Ghadia
EAElizabeth J. Andrews
Elizabeth J. Andrews
EHELIZABETH HEAD
ELIZABETH HEAD
Aquaporin-4 (AQP4) is implicated in Alzheimer's disease (AD) pathology through its role in astrocytic function, cerebrovascular integrity, and beta-amyloid (Aβ) clearance. Impaired Aβ clearance in AD is linked to changes in AQP4 distribution; however, the role of AQP4 in AD associated with Down Syndrome (DS) is poorly understood. This study investigates AQP4 protein levels, its relationship with Aβ deposition, and distribution patterns in DS. Using human post-mortem brain sections from the frontal and occipital cortex, we analyzed AQP4 and Aβ levels in samples from neurotypical controls, DS, DS with AD (DSAD), and late onset AD (LOAD). Protein levels and distribution were assessed using immunohistochemistry and immunofluorescence with quantitative imaging tools. AQP4 protein levels were higher with age in both neurotypical control and DS groups, but not in the LOAD group. AQP4 and Aβ were positively correlated with age in the frontal cortex of all groups. AQP4 and Aβ were positively correlated with each other after adjusting for age in the frontal cortex in both the control and DS groups which was not observed in the occipital cortex. In the frontal cortex of both DS and DSAD, AQP4 was more frequently distributed to the soma and proximal branches and less to astrocytic endfeet compared to the control group, consistent with previous reports of impaired glymphatic clearance and perivascular regulation. These findings support a relationship between altered AQP4 protein levels and distribution, Aβ accumulation, and region-specific vulnerability in DS and AD.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CSCherie A Stringer
Cherie A Stringer
HMHaley Miyasato
Haley Miyasato
KCKevin Camey
Kevin Camey
PNPhong Ngo
Phong Ngo
EAElizabeth J. Andrews
Elizabeth J. Andrews
EHElizabeth Head
Elizabeth Head
Background: Down syndrome (DS) is characterized by the overexpression of the amyloid precursor protein gene (APP) and pro‐inflammatory genes, leading to progressive beta‐amyloid (Aβ) accumulation. This accumulation in DS may exacerbate neuroinflammation, contributing to the pathogenesis of Alzheimer’s Disease (AD). Experimental models suggest that aquaporin 4 (AQP4), an astrocytic water channel implicated in Aβ clearance, is mislocalized with increased Aβ burden. It is unclear whether the mislocalization of AQP4 is observed and connected with reactive astrogliosis in response to Aβ and the progression of AD in DS. We hypothesize AQP4 expression is increased and mislocalized from astrocytic endfeet, contributing to an astrocytic neuroinflammatory response in DS with AD pathogenesis.Methods: This study analyzed AQP4 distribution and expression via immunohistochemistry for AQP4 in 70 frontal (FR) and 64 occipital (OC) cortical human post‐mortem brain samples. Diagnostic classes included aged controls, DS, DS with AD, and sporadic AD (sAD). Semi‐quantitative analysis compared AQP4 distribution across diagnostic classes and brain regions. AQP4 expression was quantified using QuPath. Immunofluorescence (IF) assessed co‐localization and distribution of neuroinflammatory markers complement C3 (C3) and S100β with GFAP‐labeled astrocytes.Results: AQP4 immunolabeling was observed for expression, distribution, and astrocytic morphology. In DS with AD, AQP4 was expressed away from endfeet, indicating a higher prevalence of reactive astrocytic morphologies compared with DS and control groups. Two‐Way ANOVA analysis revealed increased AQP4 expression in DS with AD compared with DS in both FR (p<0.0001) and OC (p = 0.0007) regions. IF for C3 exhibited a plaque‐like distribution and S100β co‐localized with GFAP‐labeled astrocytes in DS with AD and sAD not seen in DS and controls.Conclusion: The observed increased expression and mislocalization of AQP4 from endfeet, coupled with heightened AQP4‐labeled reactive astrocytic morphology, supports our hypothesis that AQP4 is involved in AD pathology in DS. Altered neuroimmune marker distribution and co‐localization in DS with AD, compared to DS alone, further supports the hypothesis that AQP4 localization contributes to reactive astrogliosis. Subsequent investigations will explore correlations between AQP4 localization changes, Aβ levels, and increased expression of neuroinflammatory markers, including C3 and S100β.Funding: NINDS (T32 NS121727‐01), ADRC (P30AG066519), ABC‐DS (U19AG068054), and Brightfocus (BFF17_0008).